Patterns of infection in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving 5-azacitidine. Candidates for antifungal prophylaxis

被引：0
|
作者：
Falantes, J. [1 ]
Calderon, C. [1 ]
Marquez-Malaver, F. J. [1 ]
Aguilar, M. [2 ]
Martino, M. L. [1 ]
Gonzalez, J. [1 ]
Montero, M. I. [1 ]
Parody, R. [1 ]
Espigado, I. [1 ]
Perez-Simon, J. A. [1 ]
机构：
[1] Hosp Virgen Rocio, Hematol, Inst Biomed Sevilla IBIS, Seville, Spain
[2] Hosp Virgen Rocio, Infect Dis, Seville, Spain
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70043-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-021
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [31] Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML)
    Afable, Manuel G., II
    Makishima, Hideki
    Sakaguchi, Hirotoshi
    Jerez, Andres
    Jankowska, Anna Malgorzata
    Guinta, Kathryn M.
    Abu Kar, Sara
    Traina, Fabiola
    Sugimoto, Yuka
    O'Keefe, Christine
    Tiu, Ramon V.
    Sekers, Mikkael A.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 1522 - 1523
  • [32] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 212B - 212B
  • [33] Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Al-Issa, Karam
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Jha, Babal K.
    Adema, Vera
    Advani, Anjali
    Nagata, Yasunobu
    Kuzmanovic, Teodora
    Carraway, Hetty E.
    Przychodzen, Bartlomiej
    Maciejewski, Jaroslaw P.
    Nazha, Aziz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S261 - S261
  • [34] Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States
    Albitar, Adam Zrinski
    Shah, Neil
    McCloskey, James K.
    Koprivnikar, Jamie L.
    Zhao, Jianhua
    Desai, Chirag
    Sudarsanam, Sucha
    Albitar, Maher
    Lai, Catherine E.
    BLOOD, 2018, 132
  • [35] Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors
    Jonsdottir, Gudbjorg
    Bjorkholm, Magnus
    Turesson, Ingemar
    Hultcrantz, Malin
    Porwit, Anna
    Jethava, Yogesh
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    BLOOD, 2017, 130
  • [36] How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma, David P.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (04)
  • [37] Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Al-Issa, Karam
    Hirsch, Cassandra M.
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Abuhadra, Nour
    Jha, Babal K.
    Adema, Vera
    Advani, Anjali S.
    Nagata, Yasunobu
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [38] Clinical significance of del(20q) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Tedeschi, A
    Montillo, M
    Hayes, KJ
    Di Raimondo, F
    Lerner, S
    Morra, E
    Estey, E
    Keating, MJ
    BLOOD, 2000, 96 (11) : 709A - 709A
  • [39] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
    Wang, Eunice S.
    Bell, Timothy
    Zeidan, Amer Methqal
    Bhattacharyya, Helen
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    Sallman, David A.
    DeZern, Amy E.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Roboz, Gail J.
    Sekeres, Mikkael A.
    Cluzeau, Thomas
    Sweet, Kendra L.
    McLemore, Amy F.
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Yao, Jiqiang
    Mo, Qianxing
    Nardelli, Lisa
    Al Ali, Najla
    Padron, Eric
    Korbel, Greg
    Attar, Eyal C.
    Kantarjian, Hagop M.
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2019, 134
12345